Clinical Study Results

Research Sponsor: Acerta Pharma B.V., a member of the AstraZeneca group

Drug Studied: Acalabrutinib

Study Purpose: This study was done to learn about the safety of acalabrutinib and how it works in participants with COVID-19 who need hospital care

Protocol Number: D822FC00003



Thank you

Thank you for taking part in the clinical study for the study drug acalabrutinib.

You and all of the participants helped researchers learn more about acalabrutinib to help people with COVID-19 who need hospital care.

Acerta Pharma B.V. sponsored this study and believes it is important to share the results of the study with you and the public. An independent non-profit organization called CISCRP helped prepare this summary of the study results for you. We hope it helps you understand and feel proud of your important role in medical research.

If you participated in the study and have questions about the results, please speak with the study doctor or staff at your study site.